| 000 | 01508 a2200397 4500 | ||
|---|---|---|---|
| 005 | 20250517063139.0 | ||
| 264 | 0 | _c20160926 | |
| 008 | 201609s 0 0 eng d | ||
| 022 | _a1750-7448 | ||
| 024 | 7 |
_a10.2217/imt.15.78 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aAssal, Amer | |
| 245 | 0 | 0 |
_aEmerging targets in cancer immunotherapy: beyond CTLA-4 and PD-1. _h[electronic resource] |
| 260 |
_bImmunotherapy _c2015 |
||
| 300 |
_a1169-86 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Meta-Analysis; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S.; Review | ||
| 650 | 0 | 4 | _aAnimals |
| 650 | 0 | 4 |
_aAntigens, CD _xmetabolism |
| 650 | 0 | 4 |
_aAntineoplastic Combined Chemotherapy Protocols _xtherapeutic use |
| 650 | 0 | 4 |
_aB7-H1 Antigen _xantagonists & inhibitors |
| 650 | 0 | 4 |
_aCTLA-4 Antigen _ximmunology |
| 650 | 0 | 4 | _aClinical Trials as Topic |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aImmunotherapy |
| 650 | 0 | 4 | _aMolecular Targeted Therapy |
| 650 | 0 | 4 |
_aNeoplasms _ximmunology |
| 650 | 0 | 4 |
_aProgrammed Cell Death 1 Receptor _ximmunology |
| 650 | 0 | 4 |
_aTumor Escape _xdrug effects |
| 650 | 0 | 4 |
_aTumor Necrosis Factor-alpha _xantagonists & inhibitors |
| 650 | 0 | 4 | _aLymphocyte Activation Gene 3 Protein |
| 700 | 1 | _aKaner, Justin | |
| 700 | 1 | _aPendurti, Gopichand | |
| 700 | 1 | _aZang, Xingxing | |
| 773 | 0 |
_tImmunotherapy _gvol. 7 _gno. 11 _gp. 1169-86 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.2217/imt.15.78 _zAvailable from publisher's website |
| 999 |
_c25448622 _d25448622 |
||